Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease

Learn more about:
Related Clinical Trial
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

Official Title

CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

Brief Summary

      This is a multicenter, randomized, open-label study with an active standard-of-care
      comparator (penicillamine)
    

Detailed Description

      This is a multicenter, randomized, open label study with an active standard-of-care
      comparator.

      Stable patients who are already considered to be stable on their standard-of-care
      penicillamine chelation therapy for at least 1 year will enroll in the study and enter a
      12-week Penicillamine Baseline Period comprising of 1 month (4 weeks) run-in period followed
      by a 2 month (8 weeks) evaluation period. During this time all patients will continue to take
      their current penicillamine under study conditions. At the end of the Penicillamine Baseline
      Period, patients who fulfill the protocol definition of being adequately controlled and
      tolerating penicillamine will be randomized in a 1:1 ratio to receive either TETA 4HCl or to
      continue to receive penicillamine. There is then a 24-week Post-randomization Phase
      comprising of a 1 month (4 weeks) run-in period for both treatment arms and a 5 month (20
      weeks) evaluation period.

      Patients who successfully complete the 24-week Post-randomization Phase of the study will
      have the opportunity to enter an 18 month (72 weeks) Extension Phase. Initially they continue
      to receive their allocated TETA 4HCl or penicillamine for a further 24 weeks (i.e., up to
      Week 60 of the study). Thereafter all patients will receive TETA 4HCl for 48 weeks (i.e.,
      between Week 60 and Week 108). Study clinic visits occur every 6 months (24 weeks) for all
      patients (i.e., at Weeks 60, 84 and 108).
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Serum NCC concentration

Secondary Outcome

 24-hour urinary copper excretion

Condition

Wilson Disease

Intervention

TETA 4HCL

Study Arms / Comparison Groups

 TETA 4HCL
Description:  Active Treatment

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

55

Start Date

June 4, 2018

Completion Date

January 2022

Primary Completion Date

January 2022

Eligibility Criteria

        Inclusion Criteria:

          1. Patient is able to provide, and has provided, written informed consent

          2. Written documentation has been obtained in accordance with the relevant country and
             local privacy requirements, where applicable, including: For US sites: Authorization
             for Use and Release of Health Research Study Information and for EU sites: Data
             Protection Consent

          3. Male or female, aged ≥ 18 and ≤ 75 years of age at time of consent

          4. Patient has a diagnosis of Wilson's disease, as defined by a prior or current Leipzig
             score of ≥ 4

          5. Patient's Wilson's disease is clinically stable, in the opinion of the investigator,
             and being treated with penicillamine for at least 1 year (52 weeks) prior to the
             screening/enrolment visit

          6. Patient is on a stable dose and regimen of penicillamine for at least 4 months (16
             weeks) prior to the screening/enrolment visit (other prescribed treatments for
             Wilson's disease not permitted during this study)

          7. No anticipated need that patient will require additional pharmacological therapies
             other than study medication, including prescribed zinc therapy, for the management of
             copper levels during the study

          8. Patient must be willing to maintain stable diet throughout the study, and avoid foods
             with high copper content, including the Penicillamine Baseline Period

          9. Patient considered suitable to receive therapy with both TETA 4HCl and penicillamine
             administered twice a day

         10. Negative central laboratory tests for HIV and viral hepatitis (results will be
             available after start of run-in period)

         11. For female patients of childbearing potential, negative urine pregnancy test (at
             screening/enrolment visit and prior to randomization)

         12. For females of childbearing potential, use of a reliable form of contraceptive

         13. Patient is considered as able to complete study requirements and attend the study
             visits, in the opinion of the investigator

             Additional inclusion criteria following receipt of Screening laboratory results

         14. Patient is adequately controlled and tolerating penicillamine therapy as defined by
             fulfilment of all of the following: a. Serum non-ceruloplasmin bound copper (NCC)
             level between ≥ 25 and ≤ 150 μg/L* b. 24-hour urinary copper excretion of between ≥
             100 and ≤ 900 μg/24 hours* c. Alanine transaminase (ALT) < 2 times upper limit of
             normal* d. No other laboratory or clinical findings that would prevent continuation of
             maintenance therapy, in the opinion of the investigator

             * Based on results from screening/enrolment visit samples for which can be taken
             within ± 7 days of visit. Result should be within the assay limits of quantification
             for the sample. The ranges in μmol of copper are 0.40 to 2.38 μmol/L for NCC and 1.59
             to 14.29 for 24-hour urinary copper excretion (using division by 63 of value in μg per
             Walshe, 2011). In the event that one or more of the above lab values fall outside the
             specified range, it can be repeated, including at the Week 4 and Week 8 visits.

             Additional inclusion criteria at Week 12 visit (end of Penicillamine Baseline Period)
             and prior to randomization

         15. Patient is adequately controlled and tolerating penicillamine therapy as defined by
             fulfilment of all of the following criteria:

               1. Serum non-ceruloplasmin bound copper (NCC) level between ≥ 25 and ≤ 150 μg/L*

               2. 24-hour urinary copper excretion of between ≥ 100 and ≤ 900 μg/24 hours**

               3. Alanine transaminase (ALT) < 2 times upper limit of normal*

               4. No other laboratory or clinical findings that would prevent continuation of
                  maintenance therapy, in the opinion of the investigator

                    -  Based on lab values from Week 8 visit; ** Based on lab value from Week 4
                       visit as routinely not performed at Week 8 visit, however can also be based
                       on value at Week 8 visit if a repeat (unscheduled) urinary copper excretion
                       was performed at this visit. Result should be within the assay limits of
                       quantification for the sample. The ranges in μmol of copper are 0.40 to 2.38
                       μmol/L for NCC and 1.59 to 14.29 for 24-hour urinary copper excretion (using
                       division by 63 of value in μg per Walshe, 2011). In the event that one or
                       more of the above lab values fall outside the specified range, it can be
                       repeated. The repeat value(s) must be available prior to randomization at
                       Week 12 and, if within specified range, the patient can continue to
                       randomization. If a patient fails this additional criterion at the end of
                       the Penicillamine Baseline Period, the patient can return to the start of
                       the run-in period i.e. Day 1 (but only once). A negative urinary pregnancy
                       test is also required prior to randomization for females of childbearing
                       potential.

        Exclusion Criteria:

          1. Patient is in 'de-coppering' phase of treatment for Wilson's disease, in the opinion
             of the investigator

          2. Patient evidence of uncontrolled liver disease, including but not limited to:

               1. Modified Nazer score of > 4 (result may not be available until after start of run
                  in period since based on lab results*)

               2. decompensated cirrhosis

               3. acute hemolytic anemia

               4. acute hepatitis

               5. hepatic malignancy

               6. evidence of acute liver failure

          3. Cause of patient's liver disease is due to another condition, in the investigator's
             opinion

          4. Patient has severe anemia defined as hemoglobin of ≤ 9 g/dL (result will be available
             after start of run-in period*)

          5. Patient has experienced a gastrointestinal bleed within 6 months (24 weeks) prior to
             screening/enrolment visit

          6. Patient has renal impairment defined as creatinine clearance of ≤ 30 mL/min (result
             may not be available until after start of run-in period*), or patient has nephritis or
             nephrotic syndrome, in the opinion of the investigator

          7. Patient has neurological disease that prevents swallowing of study medication (e.g.,
             requires a nasogastric feeding tube) or requires intensive in-patient medical care

          8. Patient is currently taking medication containing trientine for management of Wilson's
             disease or has taken it within 4 months (16 weeks) of screening/enrolment visit

          9. Patient is currently receiving prescribed zinc therapy for management of Wilson's
             disease or has taken it within 4 months (16 weeks) of screening/enrolment visit

         10. Patient is taking any of the following concomitant therapies: gold therapy,
             antimalarial therapy, cytotoxic drugs, oxyphenbutazone, phenyl butazone

         11. Patient has a known intolerance, allergy or sensitivity to penicillamine (that is
             uncontrolled) or to TETA 4HCl, including any component of the study medication

         12. For female patients of childbearing potential, planning a pregnancy during study
             period or currently nursing

         13. For female patients of childbearing potential, unable or unwilling to use a reliable
             form of contraceptive throughout the study

         14. Patient is currently participating in another therapeutic study, or has previously
             participated in a therapeutic study within 30 days of screening/enrolment visit (or
             longer, if local requirements specify this)

         15. Patient has any condition or in any situation which, in the investigator's opinion,
             puts the patient at significant risk, could confound study results, or may interfere
             significantly with the patient's participation in the study
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Belgium

Location Countries

Belgium

Administrative Informations


NCT ID

NCT03539952

Organization ID

GMPO-131-002


Responsible Party

Sponsor

Study Sponsor

GMP-Orphan SAS


Study Sponsor

, , 


Verification Date

June 2020